Company intelligence / Profile preview

ILC Therapeutics Ltd

Glasgow, Scotland, United Kingdomilctherapeutics.com ↗

Ownership: Private
Employees: ~14
Development stage: Preclinical

Overview

In vivo tests completed for COVID-19 drug; research shows Alfacyte is 15-20 times more effective at preventing SARS-CoV-2 spread in vitro compared to other interferons

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Hybrid interferons
Industry: Biotech

Drug pipeline

1 asset

Alfacyte

Unknown

Partnerships

University of St AndrewsDechra Pharmaceuticals PLC

Beyond the preview

Go deeper on ILC Therapeutics Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILC Therapeutics Ltd.

Explore the full profile